Dimitrios Mantzilas obtained his MSc. degree in Biochemistry from the University of Oslo in 2000.
He has 20 years of experience regarding purification technologies, automation, instrument development, kit development and resin development obtained through his work in Academia and various Pharmaceutical companies (UIO, GE Healthcare, Algeta and Bayer), his experience is spanning from early research to commercial applications.
Dimitrios Mantzilas is now the CTO at Precirix; PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
